Halma buys Dreampath Diagnostics from Summit Partners

Summit Partners has sold Dreampath Diagnostics to Halma, the London-listed group, PE Hub reported. The transaction gives Halma a provider of automated workflow systems used by anatomical pathology laboratories, with Dreampath managing more than 300 million tissue samples across its laboratory network, according to PE Hub.

The deal marks an exit for Summit, which first invested in Dreampath through a growth investment in July 2025, PE Hub reported. Since that investment, Dreampath has broadened its product and service platform, according to the report.

Dreampath operates in anatomical pathology, the laboratory discipline involved in handling and assessing tissue samples. Automated workflow systems in this setting are designed to support the movement, tracking and processing of samples through laboratory operations. For laboratory operators, such systems can be tied to throughput, traceability and quality-control processes, particularly where sample volumes are large.

PE Hub described Dreampath as a business serving anatomical pathology laboratories rather than a general diagnostics platform. Its reported scale, more than 300 million tissue samples under management across its lab network, places the company in a data- and process-intensive segment of healthcare infrastructure.

For Summit, the sale represents the private equity firm’s monetisation of a healthcare technology investment made less than a year earlier, based on the July 2025 investment timing reported by PE Hub. Growth investments typically provide capital to support expansion rather than transfer full ownership at the outset, although PE Hub did not provide further detail on the size or terms of Summit’s original investment.

For Halma, the acquisition adds a diagnostics workflow specialist to a public company portfolio. PE Hub identified Halma as London-listed, but did not report additional details on consideration, financing, regulatory approvals or expected closing conditions.

The transaction sits within a wider area of healthcare dealmaking focused on operational tools for laboratories, where buyers often look for businesses that can improve process reliability and sample handling. PE Hub reported only that Dreampath had expanded its product and service platform following Summit’s investment.

No financial terms were included in the details reported by PE Hub. The report also did not name advisers to the buyer or seller.

This story draws on original reporting from PE Hub.